Alvotech will participate in the Jefferies Global Healthcare Conference 2025, presenting business updates and hosting meetings.
Quiver AI Summary
Alvotech, a biotech company specializing in biosimilar medicines, announced its participation in the Jefferies Global Healthcare Conference taking place in New York from June 3-5, 2025. Dr. Balaji Prasad, the Chief Strategy Officer, will present an update on the company's recent business developments on June 5 at 10:30 am EDT, which will also be available via live webcast. Alvotech aims to lead in the biosimilar market with a focus on high-quality, cost-effective products. The company has launched two biosimilars and has a pipeline targeting various conditions, while forming strategic partnerships worldwide to enhance its market presence. For more information, details can be found on Alvotech’s website and investor portal.
Potential Positives
- Participation in the Jefferies Global Healthcare Conference 2025 highlights Alvotech's commitment to engaging with investors and stakeholders, enhancing its visibility in the biotech sector.
- Dr. Balaji Prasad’s presentation and the availability of a live video webcast provide an opportunity for transparent communication regarding recent business updates, which can strengthen investor confidence.
- The announcement of ongoing development in a diverse pipeline of biosimilar candidates targeting various medical conditions positions Alvotech as an innovator in the biosimilar market.
- The establishment of strategic commercial partnerships across multiple regions indicates a strong market presence and potential for revenue growth, showcasing Alvotech's global operational capabilities.
Potential Negatives
- Participation in the Jefferies Global Healthcare Conference could indicate that the company is seeking to attract attention or investment, potentially reflecting a lack of confidence in its market position or current performance.
- Limited information on recent business updates may imply challenges or uncertainties in the company’s operations or pipeline, which could raise concerns among investors.
FAQ
When is the Jefferies Global Healthcare Conference 2025?
The conference is held from June 3-5, 2025, in New York, New York.
Who will represent Alvotech at the conference?
Dr. Balaji Prasad, Chief Strategy Officer, will present updates and participate in one-on-one meetings.
What time is Alvotech's presentation at the conference?
Alvotech's presentation is scheduled for Thursday, June 5, 2025, from 10:30 am to 11:00 am EDT.
How can I access the live webcast of the presentation?
The live video webcast can be accessed at Alvotech's investor portal during the event.
What is Alvotech known for?
Alvotech specializes in developing and manufacturing biosimilar medicines for patients globally.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ALVO Hedge Fund Activity
We have seen 27 institutional investors add shares of $ALVO stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,401,421 shares (+inf%) to their portfolio in Q1 2025, for an estimated $13,551,741
- VANGUARD GROUP INC added 995,538 shares (+31.1%) to their portfolio in Q1 2025, for an estimated $9,626,852
- SCULPTOR CAPITAL LP removed 565,359 shares (-93.3%) from their portfolio in Q1 2025, for an estimated $5,467,021
- MORGAN STANLEY removed 469,680 shares (-31.7%) from their portfolio in Q1 2025, for an estimated $4,541,805
- POINTSTATE CAPITAL LP removed 67,040 shares (-5.4%) from their portfolio in Q1 2025, for an estimated $648,276
- OAKTREE CAPITAL MANAGEMENT LP removed 57,222 shares (-3.0%) from their portfolio in Q1 2025, for an estimated $553,336
- FREEGULLIVER LLC removed 43,681 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $577,899
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday June 5, 2025, at 10:30 am-11:00 am EDT (14:30-15:00 GMT / 16:30-17:00 CET).
A live video webcast of the presentation will be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/jefferies-global-healthcare-conference-nyc-2025. After the event, a recording will be available for replay for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal , and our website or follow us on social media on LinkedIn , Facebook , Instagram , and YouTube .
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
[email protected]
